ÄϹ¬28NGÏàÐÅÆ·ÅÆÁ¦Á¿

        °©Ö¢µÄÔçÆÚÕï¶ÏÊÇÈ«ÇòÖ×Áö¿ØÖÆÓëÔ¤·ÀµÄÒªº¦²½Ö裬¼°Ôç·¢ÏÖÓÐÀûÓÚÑ°ÕÒÓÐЧµÄÖÎÁÆ·½°¸´Ó¶ø½µµÍËÀÍöÂÊ¡£ÎªÁËÌá¸ß°©Ö¢»¼ÕßµÄÕï¶ÏЧÂÊ£¬¸ßÁéÃô¶ÈµÄɸ²éÒªÁìÓÈΪÖØÒª¡£

ͼƬÀ´Ô´£ºHum Genomics . 2020 May 6;14(1):15.

Ò»¡¢Ö×Áö±êÖ¾Îï

        Ö×Áö±êÖ¾ÎïÊÇ°©Ï¸°û»òÌåÄÚÆäËûϸ°ûÏìÓ¦°©Ö¢»òijЩÁ¼ÐÔ¼²²¡£¨·Ç°©ÐÔ£©×´¿ö¶ø´æÔÚ»òÓÉÆä·¢ÉúµÄÎïÖÊ¡£ËûÃÇÓÉÕý³£Ï¸°ûºÍ°©Ï¸°ûÅäºÏ·¢Éú£¬°©Ï¸°û·¢ÉúµÄÁ¿¸ü¸ß£¬¿ÉÓÃÓÚ¼ø±ðÖ×ÁöÓë·ÇÖ×Áö»ò½¡¿µ¸öÌå¡£ÕâЩÎïÖÊ¿É´æÔÚÓÚÖ×Áöϸ°ûºÍ×éÖ¯ÖУ¬Ò²¿ÉÒÔ½øÈëѪҺºÍÌåÒº£¨ÐØË®¡¢¸¹Ë®¡¢ÄÔ¼¹ÒºµÈ£©ÖУ¬Òò´Ë¿Éƾ¾ÝÆäѪҺ»òÆäËûÌåÒºÖеIJâ³ö¶ø¿¼ÂÇÖ×ÁöµÄ´æÔÚ¡£Ëæ×ÅÈ«Çò°©Ö¢¸ºµ£µÄÖðÄêÔö¼Ó£¬Ö×Áöѧר¼ÒÃÇÕýÔÚÑ°ÕÒ¾«×¼¡¢Ãô¸ÐµÄ°ÐÏòÖ×Áö¼ì²âÒªÁì²¢¼à²âÆäÉú³¤¡£

        ѪҺÖ×Áö±êÖ¾Îï¶ÔÖ×ÁöµÄ´æÔÚ¾ßÓÐÖØÒªµÄÌáʾÒâÒ壬ԽÀ´Ô½¶àµÄ³ÉΪÖ×ÁöÔçÆÚÕï¶ÏÑо¿µÄÈȵãÒýÆðÁÙ´²Ò½ÉúµÄ¹Ø×¢¡£½üÄêÀ´£¬ÑªÇåÖ×Áö±êÖ¾ÎïÖð½¥×÷ΪÆäÕï¶Ï¹¤¾ßµÄÒ»²¿ÃÅ£¬ÆäÖÐѪÇåÐÂÐÍÖ×Áö±êÖ¾Îï DR-70ÒòÆäÎÞ´´µÈ¼ì²âÓÅÊÆ£¬Öð½¥ÏÔʾ³öÖØÒª¼ÛÖµ¡£

        Ö×Áö±êÖ¾ÎïÁ¬ÐøÊÓ²ì¸üÓÐÒâÒ壬ͻȻÉý¸ßÖµµÃ×¢Ò⣬µ«ÊÇÉý¸ßʱ²»ÐÐÇáÒ×Õï¶ÏΪ¶ñÐÔÖ×Áö£¬ÐèÒª½áºÏÆäËûÏà¹Ø¼ì²é¡¢ÁÙ´²Ö¢×´¡¢Ìå¸ñ¼ì²éµÈ×ÛºÏÅжÏ¡£

ͼƬÀ´Ô´£ºJournal of Immunoassay and Immunochemistry, 31:131–147, 2010

¶þ¡¢ÑªÇåÐÂÐÍÖ×Áö±êÖ¾ÎïDR-70

        DR-70ΪÏËάÂÑ°×½µ½â¸´ºÏÎÖ×Áöϸ°ûÄܹ»´Ù½øÌåÄÚ×éÖ¯Òò×Ó¡¢ÄýѪÒò×ӵȴÙÄýÒò×ÓµÄÊÍ·Å£¬Ê¹»úÌå´¦ÓÚ¸ßÄý״̬£¬ÏËάÂÑ°×Ô­¼°ÏËάÂÑ°×ˮƽÉý¸ß£»Í¬Ê±Ö×Áöϸ°ûÒ²»á¸ß±í´ïºÏ³ÉÏËÈÜøԭ¼¤»îÎplasminogen activator£¬PA£©£¬´Ù½øÏËάÂÑ°×Ô­¼°ÏËάÂѰ׵Ľµ½â£¬¹Ê¶øѪÇåÖÐÏËάÂÑ°×½µ½â²úÎ︴ºÏÎïˮƽÉý¸ß¡£

ͼƬÀ´Ô´£ºÍøÂç

        ÒÔθ°©ÎªÀý£¬DR-70ÓëCEAµÈ°©Ï¸°û𤸽·Ö×Ó²îÒ죬ÔÚѪҺÖÐ×ÔÓÉƯ¸¡£¬ÓÚѪÇåÖк¬Á¿×ºñ£¬ÆäÔÚθ°©»¼ÕßѪҺÖеļì³öÑôÐÔÂÊ¿ÉÒÔͨ¹ýͬʱÕÉÁ¿¿ÉÄܱ»ÆäËû²âÊÔËùµÍ¹ÀµÄ¶àÖÖFDPÀ´³äµ±“°©Ö¢µÄÇçÓê±í”¡£

KaplaneMeier curves for overall survival and overall survival of gastric cancer patients who were stratified by DR-70 level.

ͼƬÀ´Ô´£ºHung Y-P, et al., The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients, Journal of the Chinese Medical Association (2018), https://doi.org/10.1016/j.jcma.2018.01.009

Èý¡¢ÐÂÐÍÖ×Áö±êÖ¾ÎïDR-70¼ì²â

        ÎÒÃÇÈ«ÐÂÍƳöÐÂÐÍÖ×Áö±êÖ¾ÎïDR-70£ºÐÂÐÍÖ×Áö±êÖ¾ÎïDR-70¼ì²âÏîÄ¿£¬ÁýÕÖ¶à¸ö¸ß·¢°©ÖÖ£¬¾«×¼¶¨Î»¸ß·çÏÕÈËȺɸ²é¡£

• ÁýÕÖ13´ó¸ß·¢°©ÖÖ

• ¸ß·çÏÕÈËȺ

- ÄêÁä40ËêÒÔÉÏ - Éú»î·½Ê½Óдý¸ÄÉÆÈËȺ£ºÎüÑÌ¡¢Òû¾Æ¡¢²»×¢ÒâÌåÓý¶ÍÁ¶ - ²¡¶¾»òϸ¾úѬȾ£¬ÈçÒҸΡ¢±û¸Î¡¢HPV¡¢ÓÄÃÅÂݸ˾úµÈ

- ´úлÀàµÄ¼²²¡£¬ÈçÌÇÄò²¡¡¢³¬ÖØ¡¢·ÊÅÖµÈ

- »·¾³ÒòËØÓ°Ï죬Èç¿ÕÆøÎÛȾ¡¢Ò»Ð©Óк¦ÎïÖʵĽӴ¥

- Ö°ÒµÏà¹ØµÄ̻¶£¬Èç¾­³£½Ó´¥·Û³¾¡¢ÃºÑÌ¡¢»¯Ñ§ÎïÖʵÈ

• ÏîÄ¿ÓÅÊÆ

? ÎÞ´´

? ¸üÒ×Íƹãʵʩ

? ¸ßÁéÃô¶È¼°ÌØÒìÐÔ

• Ñù±¾ÒªÇó

ѪÇå

²Î¿¼ÎÄÏ×

[1] Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer 2014;17:26-33.

[2] Hou JX, Yang XQ, Chen C, Jiang Q, Yang GL, Li Y. Screening the gastric cancer related tumor markers from multi-tumor markers protein chip with kappa coefficient and cost-effectiveness analysis. Hepatogastroenterology 2011;58:632-6.

[3] Wu D, Zhou X, Yang G, Xie Y, Hu M, Wu Z, et al. Clinical performance of the AMDL DR-70 immunoassay kit for cancer detection. J Immunoassay 1998;19:63-72.

[4] Lin SZ, Chen CC, Lee KC, Tseng CW, Lin HY, Chen YC, et al. DR-70 immunoassay for the surveillance of hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27:547-52.